Quan Dong Nguyen, MD, MSc
Professor of Ophthalmology
Byers Eye Institute
Spencer Center for Vision Research
Wu Tai Neurosciences Institute
Stanford University School of Medicine
Quan Dong Nguyen, MD, MSc was born in Saigon, Vietnam, and immigrated with his parents and three brothers to the United States in 1980. He is currently Professor of Ophthalmology at the Byers Eye Institute at Stanford University School of Medicine.
After completing his education at the Phillips Exeter Academy, Yale, University of Pennsylvania, and Harvard in 2001, Dr. Nguyen joined the faculty at the Wilmer Eye Institute at Johns Hopkins as Assistant Professor and then Associate Professor of Ophthalmology and Director of Medical Education. In 2013, he was appointed as the McGaw Endowed Chair in Ophthalmology, Professor and Chairman of the Department of Ophthalmology, and the Inaugural Director of the Stanley M. Truhlsen Eye Institute, as well as Assistant Dean for Translational Research at the University of Nebraska Medical Center.
Dr. Nguyen is the principal investigator for multiple clinical trials sponsored by the National Eye Institute and other organizations on macular edema (from diabetes and uveitis), neovascular age-related macular degeneration (AMD), and ocular inflammatory and uveitic diseases. Dr. Nguyen is known for his innovative work in early proof-of-concept, first-in-human clinical trials to evaluate potential pharmacotherapeutic agents for retinal vascular and uveitic diseases. He and his team were among the first scientists in the world to evaluate aflibercept for neovascular AMD and ranibizumab for diabetic macular edema (DME); the initial results of these studies served as the foundation for subsequent trials leading to the approval of these pharmacologic agents by the FDA and other regulatory authorities for the indicated diseases. Dr. Nguyen has chaired the US multi-center READ-2, READ-3, and iDEAL studies, evaluating the potential role of VEGF antagonists through different pathways for DME.
Dr. Nguyen led the SAVE and multi-centered SAVE-2 and STOP-UVEITIS studies to evaluate the role of new pharmacologic agents, including specific interleukin inhibition in uveitis and ocular inflammatory diseases. Throughout his career, Dr. Nguyen has shared his scientific work through numerous manuscripts published in the literature. He serves on the Editorial Board of several journals, including the Journal of Ophthalmic Infection and Inflammation and Ophthalmic Surgery, Laser, and Imaging – Retina, among others.
At the Byers Eye Institute at Stanford, Dr. Nguyen has an active practice for uveitis and ocular inflammatory diseases, as well as clinical and surgical retina procedures, while he continues his research in pharmacotherapy and ocular imaging. In addition, he teaches and trains students, residents, and fellows from the United States and around the world.